Srinivasan Yegnasubramanian
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (54)
Aberrant DNA methylation has been implicated in tumorigenesis and the development of lung cancer. However, Nucleoside analog DNA methyltransferase inhibitors have demonstrated clinical utility in the treatment of myelodysplastic syndrome and acute myeloid leukemia; the drugs have not shown commensurate clinical efficacy in solid tumors. Mechanisms mediating the primary resistance to DNA hypomethylating agents in solid tumors are not fully understood. Here, we hypothesized that factors that limit incorporation of nucleoside analog DNA methyltransferase inhibitors in genomic DNA may underlie the tumor cell intrinsic primary resistance to decitabine (DAC) in lung cancer. We found that RRM1 expression levels were inversely correlated with DAC incorporation rates detected by LC–MS/MS. RNA interference-mediated depletion of RRM1, the catalytic subunit of ribonucleotide reductase (RNR), or pharmacological inhibition of RNR significantly potentiated inhibition of lung cancer cell clonogenic survival in vitro and xenograft growth in vivo by DAC treatment. Additionally, RRM1 inhibition enhances DAC-mediated tumor suppressor gene reactivation and STING pathway activation via DNA damage-induced IFI16 sensing. RNR inhibition led to increased incorporation of DAC into genomic DNA by reducing the availability of dCTP. These findings nominate the promising combination therapy of DAC and RNR inhibitors as being ripe for further clinical translation.
Year:
2026
Barcode plots for ‘Ribosome Biogenesis’, ‘Cytoplasmic Translation’, and ‘tRNA Processing’ pathways in PIN samples. All three pathways are positively enriched in MYC-PIN and BMPC-PIN samples, and negatively enriched in PTEN-Null PIN samples.
Year:
2026
Volcano plots for PTEN-Null PIN, MYC-PIN, and BMPC-PIN compared to their respective wild-type lobes with differentially expressed genes (yellow), CCP score genes (labeled), and genes in proliferation associated GO-BP pathways (blue) mitotic spindle organization (A), cell division (B), chromosome segregation (C), DNA replication (D), G2/M transition mitotic cytokinesis (E), and cell cycle (F). (G) Volcano plots depicting the top PC1 genes that drove enrichment of the proliferation associated GO-BP pathways in A-F (blue).
Year:
2026
Differential expression analysis of MYC PIN samples compared to FVB, and GSEA. Leading edge genes from GSEA using 'Dang MYC Bound' gene set for MYC PIN, BMPC PIN, and BMPC Primary samples compared with FVB samples.
Year:
2026
GSEA enrichment plots of the 20 gene sets with highest (positive enrichment) and lowest (negative enrichment) normalized enrichment scores for Pten-Null PIN, MYC-PIN, and BMPC-PIN compared to their FVB counterparts.
Year:
2026
Wild-type FVB, MYC-PIN, PTEN-Null PIN, BMPC-PIN, and BMPC primary tissue stained with H&E, and IHC staining for PTEN and phospho-AKT. Positive phospho-AKT staining in the epithelium of FVB and PIN samples is concordant with negative staining for PTEN. All tumor cells stain positively for phospho-AKT and negatively for PTEN.
Year:
2026
IHC staining for RPS2 in wild-type FVB, PTEN-Null PIN, MYCPIN,and BMPC-PIN, and antibody validation. A-B) PIN lesions with PTEN loss have decreased epithelial RPS2 compared to wild-type luminal epithelial cells. C-D) Higher power view of A and B. E-H) PIN lesions with MYC overexpression (MYC PIN [E-F] and BMPC PIN) have increased RPS2 staining, with the strongest staining observed in BMPC PIN [G-H]. I) Western blot from prostate cancer cell lines shows RPS2 antibody specificity by western blot analysis by showing a single band at the predicted molecular weight (37 kDa). Beta-Actin was used as a loading control.
Year:
2026
Prostate cancer ranges from indolent to rapidly progressive. An elevated cell proliferation index portends poor outcomes, yet the molecular alterations essential for increased cell proliferation remain ill-defined. Gain of MYC combined with biallelic PTEN loss predicts prostate cancer mortality. Prior studies have shown that combined MYC overexpression and Pten loss, driven by the Hoxb13 locus, results in prostatic intraepithelial neoplastic (PIN) lesions that progress to metastatic disease (BMPC mice). Yet, single gene alterations in these mice result only in PIN lesions. In this study, we performed transcriptomic profiling of PIN lesions from each of the three genotypes. Whereas MYC alone resulted in increases in genes related to cell-cycle regulation/cell division, combined MYC and Pten loss led to a further and more consistent increase and a synergistic cell-cycle progression. Increased ribosome biogenesis/translation is required for cell proliferation. Whereas MYC alone increased 45S rRNA and most components of the translation machinery, these were more strongly induced in BMPC mice. Surprisingly, Pten loss alone resulted in a downregulation of translation machinery genes, which could explain the absence of biallelic PTEN loss in human PIN lesions and early carcinomas. Some MYC targets were increased only after Pten loss, indicating Pten loss increases MYC activity. Implications: Increased cell cycle and translational machinery gene induction may explain the synergy between MYC and PTEN loss for increasing prostate cancer cell proliferation and disease aggressiveness. These results provide further support for the therapeutic targeting of translation in prostate cancer.
Year:
2026
Gene expression across five translation-related pathways for Pten-Null PIN samples is comparable to or less than wild-type samples, and expression increases in MYC-PIN and BMPC-PIN, with expression of some genes increasing even higher in primary and metastatic samples.
Year:
2026
/SUMMARY The cellular composition and disease susceptibilities of the distinct zones of the human prostate remain incompletely understood. Through extensive single-cell RNA sequencing (scRNA-seq) of benign regions from prostatectomy specimens, we identified a basal cell population expressing WIF1, VCAN , and NRG1 , among other genes, that was significantly enriched in the transition zone (TZ). Benign prostatic hyperplasia (BPH) is a common condition that causes widespread morbidity and is nearly exclusively localized to the TZ. Analysis of previously published scRNA-seq datasets further confirmed that WIF1 + basal cells were significantly enriched in BPH compared to normal prostate. Pathway and cell-cell communication analyses revealed that this basal subtype is associated with programs related to cell proliferation, epithelial-mesenchymal transition (EMT), angiogenesis, and hormone response. Together, the molecular signature, zonal distribution, and pathway enrichment suggest that TZ-enriched WIF1 + basal cells may contribute to BPH pathogenesis by promoting epithelial and stromal remodeling.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (20)
Mohamad Allaf
Department Director
Johns Hopkins University
Shawn Lupold
The Catherine Iola and J. Smith Michael Distinguished Professor of Urology
Johns Hopkins University School of Medicine
Michael Dyer
Chair
St. Jude Children's Research Hospital
Yasutomo Nakai
Osaka International Cancer Institute
William Nelson
Professor and Director
Johns Hopkins University
Ridwan Alam
Assistant Professor
Northwestern University
Alison Klein
Professor
-
Jelani Zarif
Associate Professor
Johns Hopkins University
W. Nathaniel Brennen
Associate Professor
Johns Hopkins University School of Medicine
Rana Rais
Johns Hopkins University
Masashi Nakayama
Osaka International Cancer Institute
Beisi Xu
Principal Bioinformatics Research Scientist
St. Jude Children's Research Hospital
Sudipto Ganguly
Assistant Professor
Johns Hopkins University
Angelo De Marzo
Professor
Johns Hopkins University School of Medicine
Christopher Heaphy
Associate Professor
Boston University School of Medicine
Barbara S. Slusher
Johns Hopkins University School of Medicine
Jonathan D. Powell
Johns Hopkins University School of Medicine
Charles Bieberich
Professor
University of Maryland Baltimore County
Elana Fertig
Assistant Professor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Drew Pardoll
Professor
Johns Hopkins University
Make your next move.
Prepare your application
Review drafts before you send them.